2018 Influenza Season

This website and the national annual influenza promotional campaign is brought to you by The Immunisation Advisory Centre (IMAC) and the National Influenza Strategy Group (NISG).

Influenza Immunisation Programme goals

• Vaccinate 75% of the population aged 65 years or older against influenza annually
• Improve influenza immunisation coverage for people aged under 65 years with certain medical conditions, and pregnant women
• Improve influenza immunisation uptake for healthcare workers
• 80% of District Health Board-based healthcare workers are vaccinated against influenza annually
• Distribute more than 1.2 million influenza vaccine doses annually, i.e. protect more than 25% of the community
 

Important Information

INFLUVAC® (trivalent influenza vaccine) overview – *NEW* fact sheet 3 July 2018

2018 Vaccine order form – Updated 29 June 2018

Funded influenza vaccines for 2018:

INFLUVAC® TETRA (quadrivalent)
For adults and children aged 3 years or older. 

FLUARIX® TETRA (quadrivalent) *OUT OF STOCK*
INFLUVAC® (trivalent) *REPLACES FLUARIX TETRA*
For children aged under 3 years, i.e. 6–35 months. 

IMPORTANT NOTE: INFLUVAC® and INFLUVAC® TETRA packaging is very similar. Spot the package differences when you select influenza vaccine from the fridge and check the syringe label before you vaccinate.

INFLUVAC® dose for children aged under 3 years, i.e. 6–35 months, is a half dose of 0.25 mL

The three influenza strains included in both the trivalent and quadrivalent vaccines are:

•  A/Michigan/45/2015 (H1N1) pdm09- like virus
•  A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
•  B/Phuket/3073/2013-like virus

The additional influenza strain included in the quadrivalent vaccines is:
•  B/Brisbane/60/2008-like virus

Minimum order requirements
The total influenza vaccine order must meet minimum quantities as follows:

March April May June July Aug-Dec
Min 60 doses Min 60 doses Min 60 doses Min 30 doses Min 20 doses Min 10 doses

New influenza vaccination precaution

Influenza vaccination may be contraindicated or need to be delayed for people receiving any of the following four new cancer treatments: 

  • atezolizumab (Tecentriq®),
  • ipilimumab (Yervoy®),
  • nivolumab (Opdivo®) 
  • pembrolizumab (Keytruda®)

These are the only four cancer treatements in New Zealand that require influenza vaccination to be delayed.

The immune-stimulant actions of these treatments on the immune system increase a person’s risk of developing autoimmune conditions.

It is not known whether receipt of an influenza vaccine whilst receiving these treatments or for up to six months after treatment increases a theoretical risk of triggering the
occurrence of these side effects.

Please contact the person’s oncologist or 0800 IMMUNE (0800 466 863) for current advice about influenza vaccination for these people BEFORE administering the vaccine.
(page 16 in the Flu kit)

Vaccine comparison chart – Updated 1 July 2018

References for 2018 Influenza Kit